Epidermal Growth Factor Signaling Pathway and Molecular Oncology
Course Logistics and Administrative Information
Lecture Date: September 23, 2026.
Discussions: Scheduled for this week and next week.
Homework: Problem sets posted later today.
Review Sessions:
General Review Session: Thursday, September 24, 2026, at 7:00 PM in Mahar Auditorium.
Exam 1 Review Session: Wednesday, September 20, 2026, at 7:00 PM in Mahar Auditorium.
Exam 1 Details:
Date & Time: Thursday, October 1, 2026, from 7:00 PM to 9:00 PM.
Duration: Exam is written to be comfortably completed in hour, but hours are provided.
Practice Exam: Posted over the weekend.
Exam Room Assignments (by Last Name):
A – Orsman: Mahar Auditorium
Orsman – White: Morrill N375
Williams – Z: Morrill 319
BioPioneers: Morrill N326
Spindle Assembly Checkpoint and Anaphase Progression

Molecular Mechanism of Mitotic Control:
Checkpoint Activation: Unattached kinetochores release chemical signals that cause to bind .
Kinetochore Attachment: Once all kinetochores are properly attached to spindle fibers, releases , which then combines with the Anaphase-Promoting Complex ().
Ubiquitination: The active complex ubiquitinates .
Proteolysis: is destroyed via proteasomal degradation, releasing the active enzyme .
Cleavage of Cohesin: cleaves and destroys , the protein complex holding sister chromatids together.
Anaphase Onset: Sister chromatids separate, and mitosis proceeds to anaphase.
Kinase Cascade Dynamics and Regulation

General Kinase Cascade Architecture:
Extracellular signal binds to Receptor ().
Activated Receptor phosphorylates Target Kinase 1 ().
Active phosphorylates Target Kinase 2 ().
Active phosphorylates Transcription Factor ().
Phosphorylated activates RNA Polymerase () to transcribe target genes.
Phosphatase Deactivation and Protein Turnover:
A phosphatase targeting turns off immediately by removing its phosphate group.
remains active () until natural protein turnover degrades the phosphorylated copies.
New molecules are synthesized in an unphosphorylated (inactive) state.
Without active , gene expression for the phosphatase ceases, and existing phosphatase proteins gradually disappear via standard protein turnover.
Crosstalk and Pathway Regulation:
Signaling pathways can intersect, where components of Pathway () regulate Pathway (), modulating expression between specific target gene sets (e.g., Light Genes vs. Other Genes).
Epidermal Growth Factor Receptor (EGFR) Architecture

Receptor Structure:
(also designated or ) is a Receptor Tyrosine Kinase () spanning the cell membrane.
Extracellular Domain: Composed of four distinct domains:
Domain I and Domain III: Closely related in sequence; participate directly in ligand binding.
Domain II and Domain IV: Closely related in sequence; contain structural loops including the domain II dimerization arm.
Cytoplasmic Domain: Contains an intrinsic protein tyrosine kinase catalytic core, a juxtamembrane segment, and a C-terminal tail with key tyrosine residues (, , , , , , ).
Conformational Switching and Dimerization:
Tethered Inactive Conformation: In the absence of ligand, exists as a monomer. The -hairpin dimerization arm of domain II intramolecularly binds to domain IV, preventing dimerization.
Ligand Binding: Ligand binding (e.g., , , , Amphiregulin/, Epiregulin/, Epigen/, Betacellulin/) occurs simultaneously across domains I and III.
Un-tethering: Binding induces a structural reorganization that extends the extracellular region, exposing the domain II dimerization arm.
Dimerization: Two ligand-bound monomers dimerize through reciprocal interactions between exposed dimerization arms.
Asymmetric Kinase Activation:
Dimerization brings cytosolic kinase domains into proximity, forming an asymmetric kinase domain dimer.
The C-lobe of the Donor Kinase docks against the N-lobe of the Acceptor Kinase.
This physical interaction pushes the acceptor kinase's activation loop out of its catalytic active site, allowing and protein substrates to bind.
The activated acceptor kinase then transphosphorylates specific tyrosine residues on the C-terminal tails of both receptor subunits.
The Ras/RAF/MEK/ERK (MAPK) Pathway Cascade

Nomenclature and Biochemical Functions:
: Epidermal Growth Factor (Extracellular signal ligand).
: Epidermal Growth Factor Receptor (Receptor Tyrosine Kinase).
: Growth Factor Receptor-Bound Protein 2 (Adapter protein containing one domain and two domains).
: Son of Sevenless (Guanine Nucleotide Exchange Factor, or ).
: Rat Sarcoma Virus Protein (Small monomeric GTPase tethered to the inner leaflet of the plasma membrane via a C-terminal lipid modification).
: Neurofibromin 1 (GTPase Activating Protein, or ).
: Rapidly Accelerated Fibrosarcoma Kinase ( / Serine/Threonine Kinase).
: Mitogen-Activated Protein Kinase Kinase ( / Dual-specificity Kinase).
: Mitogen-Activated Protein Kinase / Extracellular Signal-Regulated Kinase ().
Step-by-Step Activation Sequence:
Ligand Binding & Autophosphorylation: binds , driving dimerization and trans-autophosphorylation of cytosolic tyrosine residues.
Adapter Recruitment: Phosphotyrosines on serve as high-affinity docking sites for the domain of .
GEF Translocation: uses its domains to bind proline-rich regions on , recruiting from the cytoplasm to the membrane.
Ras Activation: Membrane-bound acts on inactive , promoting the release of and binding of abundant cellular to generate active .
RAF Recruitment: Active binds directly to the Ras Binding Domain () of .
RAF Activation: Binding to brings to the plasma membrane and relieves its autoinhibition. activation is mediated by conformational change upon binding , not by direct phosphorylation.
Phosphorylation Cascade:
Active phosphorylates on serine/threonine residues, activating .
Active phosphorylates on threonine and tyrosine residues (), activating .
Nuclear Translocation: Active, phosphorylated translocates from the cytoplasm into the nucleus.
Transcriptional Activation: phosphorylates nuclear transcription factors (e.g., , , , / AP-1 Complex), stimulating expression of genes such as Cyclin D1, which drives progression from to phase in the cell cycle.
Parallel EGFR Signaling Pathways:
Pathway: activates (via or ), converting to . phosphorylates , which inhibits to activate . This pathway blocks apoptosis, promotes cell survival, cell growth, angiogenesis, and migration.
Molecular Regulation of G-Proteins

Chemical Structures of Nucleotides:
: Guanine-nucleotide Di-Phosphate (contains two phosphate groups attached to ribose and guanine base).
: Guanine-nucleotide Tri-Phosphate (contains three phosphate groups attached to ribose and guanine base).
Regulatory Proteins:
(Guanine Nucleotide Exchange Factor):
Function: Catalyzes the release of from , allowing to enter the binding pocket, converting to its active state.
Human : .
Functional State: switch.
(GTPase Activating Protein):
Function: Stimulates the intrinsic GTPase activity of , enhancing the rate of hydrolysis into , converting back to its inactive state.
Human : (Neurofibromin 1).
Functional State: switch.
GTP Hydrolysis Reaction Equation:
Dual Functions of Ras:
RAF Activation: Requires bound to .
Intrinsic GTPase Activity: Hydrolyzes to to shut itself off.
Timeline of Functional States:
Pre-signaling: bound to . -activating activity is OFF; GTPase activity is OFF.
Signal On: activation recruits , exchanging for . -activating activity turns ON.
Signal Off: () binds , triggering intrinsic GTPase activity. is hydrolyzed to , turning -activating activity OFF. activity is brief and terminates once is formed.
EGFR Endocytosis and Attenuation
Endocytic Trafficking Modes:
Induction: binding and receptor activation stimulate proteins to assemble a cage-like structure around the receptor-containing membrane regions, forming Clathrin-coated pits that pinch off into vesicles and travel to the endosome.
Recycling Mode: The receptor-ligand complex dissociates in acidic endosomes; phosphates are removed, and receptors are returned to the cell membrane to function again.
Destruction Mode: Receptors are routed to lysosomes (the vesicular functional equivalent of the proteasome) where both ligand and receptor proteins are degraded, downregulating receptor density on the cell surface.
Receptor Expression Density and Dimerization Behavior:
Normal Cells: Express approximately receptors on their cell surface.
Cancer Cells: Overexpress to levels exceeding receptors per cell.
Structural Unique Feature of : () cannot directly bind or any known soluble ligand because its extracellular binding pocket is closed. However, its domain II dimerization arm is constitutively exposed ("lifted").
Heterodimerization: heterodimerizes with ligand-bound or at extremely low concentrations of , activating strong downstream signals.
Homodimerization: At hyper-dense levels ( receptors/cell), monomers spontaneously encounter each other and form homodimers, activating signaling completely independent of signal.
Therapeutic Targets and Inhibitory Strategies

Targeted Pharmacological Inhibitors:
Herceptin (Trastuzumab): Monoclonal antibody targeting the extracellular domain of . Inhibits both homodimerization and heterodimerization of .
Clinical Efficacy: Improves 5-year disease-free survival from to (, Hazard Ratio ); improves overall survival with Hazard Ratio ().
Tarceva (Erlotinib): Small molecule inhibitor blocking the cytosolic ATP-binding kinase domain of .
Daraxonrasib: Small molecule inhibitor directly targeting .
Vemurafenib: Specific kinase inhibitor targeting active .
Selumetinib: Specific kinase inhibitor targeting active .
Beroterkib: Specific kinase inhibitor targeting active .
Conceptual Analysis of Pathway Mutations (Cancer Mechanisms vs. Inhibition):
Mutations that increase pathway signaling and promote cancer:
Loss-of-function mutation in ().
Point mutations blocking the intrinsic GTPase activity of .
Constitutively active ().
Mutations in driving receptor dimerization/kinase activity without ligand.
Amplification/over-expression of or genes.
Constitutively active or kinase domain activity.
Unphosphorylated gaining aberrant nuclear entry.
Strategies that block hyperactive pathway signaling:
Blocking dimerization using .
Pharmacological inhibition of tyrosine kinase activity ().
Blocking the -binding domain () on to prevent contact.
Direct inhibition of , , or kinase domains.